IRulya Therapeutics Inc. (IRLA)
Nasdaq · Healthcare · Biotechnology
$31.67−4.49%as of Nov 5, 2026, 1:49 AM ET
- Market cap
- $32.2M
- 52-week range
- $15.10 – $910.00
- 52-week change
- −89.51%
- EPS (trailing)
- −$214.01
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Net income
- −$84.0M
- Diluted EPS
- −$1.68
- Free cash flow
- −$41.8M
From the company’s annual report on SEC EDGAR.
About IRulya Therapeutics Inc.
IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene. Its AIDE technology platform is a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells and consists of automated equipment, the RCL, a sterile single-use consumable treatment kit comprising medical device kits, syringe kits, and process solutions. IRulya Therapeutics Inc. was formerly known as Quince Therapeutics, Inc. and changed its name to IRulya Therapeutics Inc. in October 2026. The company was incorporated in 2012 and is headquartered in New Haven, Connecticut.
Headquarters: New Haven, United States · 38 employees · irulya.com